Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Avacta To Evaluate Affimers As Checkpoint Inhibitors, Anticoagulants

This article was originally published in The Pink Sheet Daily

Executive Summary

After raising $34 million from Britain’s stock market, the U.K. biotech now plans to develop its Affimer proteins as therapeutics as well as research reagents, to enable two complementary strands of business.

Advertisement

Related Content

Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register